1h Free Analyst Time
The publisher has been monitoring the liquid biopsy market and it is poised to grow by $1.74 bn during 2022-2026, accelerating at a CAGR of 18.77% during the forecast period. The report on the liquid biopsy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of cancer, growing focus on personalized medicine for cancer care, and increasing focus on early detection of cancer.
The liquid biopsy market analysis includes the technology segment and geographic landscape.
The liquid biopsy market is segmented as below:
By Technology
- CTC and ctDNA
- exosome and RNA
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the increasing funding/investment for fluid biopsy as one of the prime reasons driving the liquid biopsy market growth during the next few years. Also, strategic partnerships and M&A and emerging applications of fluid biopsy will lead to sizable demand in the market.
The report on liquid biopsy market covers the following areas:
- Liquid biopsy market sizing
- Liquid biopsy market forecast
- Liquid biopsy market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading liquid biopsy market vendors that include AccuraGen Holdings, Adaptive Biotechnologies Corp., ANGLE Plc, Bio Rad Laboratories Inc., Biocept Inc., CellMax Inc., Epigenomics AG, F. Hoffmann La Roche Ltd., GeneFirst Ltd., Guardant Health Inc., HansaBioMed Life Sciences Ltd., Illumina Inc., MDNA Lfe Sciences Inc., MDxHealth Group, NeoGenomics Laboratories Inc., QIAGEN NV, Rarecells Inc., SAGA Diagnostics AB, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc. Also, the liquid biopsy market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Technology
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global liquid biopsy market: AccuraGen Holdings, Adaptive Biotechnologies Corp., ANGLE Plc, Bio Rad Laboratories Inc., Biocept Inc., CellMax Inc., Epigenomics AG, F. Hoffmann La Roche Ltd., GeneFirst Ltd., Guardant Health Inc., HansaBioMed Life Sciences Ltd., Illumina Inc., MDNA Lfe Sciences Inc., MDxHealth Group, NeoGenomics Laboratories Inc., QIAGEN NV, Rarecells Inc., SAGA Diagnostics AB, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is increasing funding/investment for fluid biopsy.`
According to the report, one of the major drivers for this market is the increasing incidence of cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AccuraGen Holdings
- Adaptive Biotechnologies Corp.
- ANGLE Plc
- Bio Rad Laboratories Inc.
- Biocept Inc.
- CellMax Inc.
- Epigenomics AG
- F. Hoffmann La Roche Ltd.
- GeneFirst Ltd.
- Guardant Health Inc.
- HansaBioMed Life Sciences Ltd.
- Illumina Inc.
- MDNA Lfe Sciences Inc.
- MDxHealth Group
- NeoGenomics Laboratories Inc.
- QIAGEN NV
- Rarecells Inc.
- SAGA Diagnostics AB
- Siemens Healthcare GmbH
- Thermo Fisher Scientific Inc.
